Autolus Therapeutics plc
Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.
AUTL | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- THE MEDIAWORKS, LONDON
- Website:
- https://www.autolus.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune diseases. The company specializes in Chimeric Antigen Receptor (CAR) T cell therapies, utilizing its advanced cell programming capabilities and proprietary manufacturing processes to engineer a patient's own T cells to target and destroy diseased cells. Autolus is building a fully integrated company with a pipeline of precise, controlled, and highly active product candidates targeting hematological malignancies and solid tumors. Its lead program, obecabtagene autoleucel (obe-cel), is focused on treating adult Acute Lymphoblastic Leukemia (ALL).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Autolus Therapeutics plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Autolus Therapeutics plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Autolus Therapeutics plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
